Ariad (ARIA) Misses 4Q EPS Estimates

Ariad Pharmaceuticals Inc. (ARIA) shares are up 2.18% to $7.50 in pre-market trading Thursday following the company’s fourth quarter earnings results. The integrated global oncology firm reported EPS, excluding non-recurring items, of ($0.03) per share on revenues of $66.8 million, up 694.3% from a year ago. Analysts were expecting EPS of ($0.14) on revenues of […] View the full post at: Ariad (ARIA) Misses 4Q EPS Estimates Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock